Dlouhodobé přežití pacienta s primárně metastazujícím karcinomem prostaty - kazuistika

06/2020

MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení LF MU a FN u sv. Anny v Brně

SUMMARY

There were limited options for patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel failure or resistance, but now the approved treatment choices for these patients have expanded to include abiraterone acetate, cabazitaxel, enzalutamide and radium-223 dichloride. Although each of these agents has been shown to convey significant survival benefit as a monotherapy, findings suggest that sequence such innovative strategies with traditional treatments may achieve additive or synergistic effects, further augmenting patient benefit.

Key words

metastatic prostate cancer, androgen-deprivation therapy, cabazitaxel, enzalutamide, radium-223 dichloride